Natixis Purchases 49,953 Shares of Moderna, Inc. (NASDAQ:MRNA)

Natixis grew its position in Moderna, Inc. (NASDAQ:MRNA) by 78.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 113,966 shares of the company’s stock after acquiring an additional 49,953 shares during the quarter. Natixis’ holdings in Moderna were worth $4,739,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB lifted its position in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. Venturi Wealth Management LLC raised its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after buying an additional 664 shares in the last quarter. Compass Planning Associates Inc bought a new position in shares of Moderna during the 4th quarter worth about $37,000. Crowley Wealth Management Inc. acquired a new stake in shares of Moderna during the 4th quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 1.9 %

Shares of MRNA stock opened at $24.72 on Monday. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47. The firm has a market cap of $9.56 billion, a price-to-earnings ratio of -2.66 and a beta of 2.23. The stock has a 50-day moving average price of $30.84 and a 200 day moving average price of $39.49.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MRNA shares. Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Thursday. Leerink Partners reduced their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Finally, Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.